A Drug That's Ready to Lose
Motley Fool
Will There Ever Be an Obesity Drug Blockbuster?
Motley Fool
This Obesity Bet Just Became More Attractive
Motley Fool
Six Things to Watch at Biotech CEO Conference
Minyanville
EnteroMedics: Fat Zapper or Pulsing Placebo?
TheStreet.com
3 Horrendous Health-Care Stocks This Week
Motley Fool
Arena Shares Drop on European Questions
Motley Fool
The Biggest Loser in the Obesity Drug Market
Motley Fool